Company intelligence / Profile preview

Hangzhou Hezheng Pharmaceutical

Hangzhou, Zhejiang, Chinahsbiopharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

Hangzhou Hezheng Pharmaceutical is an innovative Chinese biotech/pharma company focused on developing novel small molecule drugs—especially PROTACs—for oncology indications. Its lead asset has reached Phase 3 for peripheral T-cell lymphoma. The pipeline includes multiple programs targeting kinases and apoptosis regulators relevant to hematological malignancies. The company has received national innovation awards in China for its R&D achievements. No commercialized products yet reported.

Therapeutic areas: Oncology
Modalities: Small moleculeProteolysis-targeting chimera therapy (PROTAC)Antibody-drug conjugateMolecular glue therapyChemical drugs
Industry: Biotech

Drug pipeline

1 asset

HZ-H08905 (Hangzhou Hezheng Pharmaceutical)

Unknown

Beyond the preview

Go deeper on Hangzhou Hezheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Hezheng Pharmaceutical.

Explore the full profile